Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HML002
MIFTS: 65

Hemolytic Anemia

Categories: Blood diseases, Genetic diseases, Immune diseases, Metabolic diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Hemolytic Anemia

About this section

MalaCards integrated aliases for Hemolytic Anemia:

Name: Hemolytic Anemia 39 12 30 6 15 17 64
Anemia, Hemolytic 45 41 74
Anemia Hemolytic 12 56

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Metabolic diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:583
MeSH 45 D000743
NCIt 51 C34376
SNOMED-CT 69 61261009
ICD10 34 D55-D59
UMLS 74 C0002878
Sources

Summaries for Hemolytic Anemia

About this section
PubMed Health : 64 About hemolytic anemia: Hemolytic anemia (HEE-moh-lit-ick uh-NEE-me-uh) is a condition in which red blood cells are destroyed and removed from the bloodstream before their normal lifespan is over.Red blood cells are disc-shaped and look like doughnuts without holes in the center. These cells carry oxygen to your body. They also remove carbon dioxide (a waste product) from your body.Red blood cells are made in the bone marrow—a sponge-like tissue inside the bones. They live for about 120 days in the bloodstream and then die.White blood cells and platelets (PLATE-lets) also are made in the bone marrow. White blood cells help fight infections. Platelets stick together to seal small cuts or breaks on blood vessel walls and stop bleeding.When blood cells die, the body's bone marrow makes more blood cells to replace them. However, in hemolytic anemia, the bone marrow can't make red blood cells fast enough to meet the body's needs.Hemolytic anemia can lead to many health problems, such as fatigue (tiredness), pain, irregular heartbeats called arrhythmias (ah-RITH-me-ahs), an enlarged heart, and heart failure.

MalaCards based summary : Hemolytic Anemia, also known as anemia, hemolytic, is related to congenital nonspherocytic hemolytic anemia and pyruvate kinase deficiency of red cells, and has symptoms including icterus An important gene associated with Hemolytic Anemia is SPTB (Spectrin Beta, Erythrocytic), and among its related pathways/superpathways are Metabolism and Glycosaminoglycan metabolism. The drugs Omeprazole and Iron have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and testes, and related phenotypes are no effect and Increased simian virus 40 (SV40) infection

Wikipedia : 77 Hemolytic anemia is a form of anemia due to hemolysis, the abnormal breakdown of red blood cells (RBCs),... more...

Sources

Related Diseases for Hemolytic Anemia

About this section

Diseases in the Hemolytic Anemia family:

Anemia, Autoimmune Hemolytic Congenital Hemolytic Anemia
Hemolytic Anemia Due to Erythrocyte Adenosine Deaminase Overproduction

Diseases related to Hemolytic Anemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 592)
# Related Disease Score Top Affiliating Genes
1 congenital nonspherocytic hemolytic anemia 34.1 G6PD GPI NT5C3A PKLR
2 pyruvate kinase deficiency of red cells 34.0 G6PD PKLR
3 congenital hemolytic anemia 33.9 ANK1 G6PD GPI HBB PKLR SPTA1
4 glucosephosphate dehydrogenase deficiency 33.1 G6PD HBB
5 hereditary spherocytosis 33.0 ANK1 EPB42 G6PD HBB PKLR SLC4A1
6 pyropoikilocytosis, hereditary 32.9 SPTA1 SPTB
7 glucosephosphate isomerase deficiency 32.7 G6PD GPI
8 glutathione synthetase deficiency 32.6 G6PD GSS
9 spherocytosis, type 3 32.1 HBB SPTA1
10 hereditary elliptocytosis 30.5 ANK1 SLC4A1 SPTA1 SPTB
11 malaria 30.4 ADAMTS13 G6PD HBB PKLR SLC4A1
12 beta-thalassemia 30.4 G6PD HBB SPTB
13 kernicterus 30.0 G6PD SLC4A1
14 hemolytic anemia, nonspherocytic, due to hexokinase deficiency 12.7
15 uridine 5-prime monophosphate hydrolase deficiency, hemolytic anemia due to 12.7
16 gamma-glutamylcysteine synthetase deficiency, hemolytic anemia due to 12.6
17 warm antibody hemolytic anemia 12.6
18 renal tubular acidosis, distal, with hemolytic anemia 12.5
19 adenylate kinase deficiency, hemolytic anemia due to 12.5
20 drug-induced autoimmune hemolytic anemia 12.5
21 glutathione synthetase deficiency of erythrocytes, hemolytic anemia due to 12.5
22 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 12.5
23 hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency 12.5
24 anemia, autoimmune hemolytic 12.5
25 hemolytic anemia, congenital, x-linked 12.4
26 mixed-type autoimmune hemolytic anemia 12.3
27 systemic lupus erythematosus with hemolytic anemia 1 12.3
28 autoimmune hemolytic anemia, warm type 12.3
29 hemolytic anemia, lethal congenital nonspherocytic, with genital and other abnormalities 12.2
30 adenosine deaminase, elevated, hemolytic anemia due to 12.2
31 hemolytic anemia with thermal sensitivity of red cells 12.2
32 hemolytic anemia due to glutathione reductase deficiency 12.2
33 lymphopenic hypergammaglobulinemia, antibody deficiency, autoimmune hemolytic anemia, and glomerulonephritis 12.1
34 neonatal autoimmune hemolytic anemia 12.1
35 autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome 12.1
36 hemolytic anemia due to erythrocyte adenosine deaminase overproduction 12.1
37 triosephosphate isomerase deficiency 12.1
38 thrombotic thrombocytopenic purpura, congenital 12.1
39 paroxysmal cold hemoglobinuria 12.0
40 glut1 deficiency syndrome 2 12.0
41 evans' syndrome 12.0
42 glucose phosphate isomerase deficiency 12.0
43 glutathione peroxidase deficiency 12.0
44 cold agglutinin disease 12.0
45 hemolytic-uremic syndrome 11.9
46 anemia, nonspherocytic hemolytic, due to g6pd deficiency 11.9
47 rh-null, regulator type 11.8
48 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 11.8
49 phosphoglycerate kinase deficiency 11.8
50 erythrocytosis, familial, 8 11.7

Graphical network of the top 20 diseases related to Hemolytic Anemia:



Diseases related to Hemolytic Anemia
Sources

Symptoms & Phenotypes for Hemolytic Anemia

About this section

UMLS symptoms related to Hemolytic Anemia:


icterus

GenomeRNAi Phenotypes related to Hemolytic Anemia according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 ADAMTS13 AK1 ALDOA ANK1 CD59 EPB42
2 Increased simian virus 40 (SV40) infection GR00356-A-2 9.13 HK1 PGK1 PKLR

MGI Mouse Phenotypes related to Hemolytic Anemia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 ADAMTS13 ANK1 CD59 EPB42 G6PD GPI
2 homeostasis/metabolism MP:0005376 9.8 ADAMTS13 AK1 ANK1 CD59 EPB42 G6PD
3 mortality/aging MP:0010768 9.4 ADAMTS13 ANK1 CD59 G6PD GCLC GPI
Sources

Drugs & Therapeutics for Hemolytic Anemia

About this section

PubMedHealth treatment related to Hemolytic Anemia: 64

Treatments for hemolytic anemia include blood transfusions, medicines, plasmapheresis (PLAZ-meh-feh-RE-sis), surgery, blood and marrow stem cell transplants, and lifestyle changes.People who have mild hemolytic anemia may not need treatment, as long as the condition doesn't worsen. People who have severe hemolytic anemia usually need ongoing treatment. Severe hemolytic anemia can be fatal if it's not properly treated.

Drugs for Hemolytic Anemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 520)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1 73590-58-6 4594
2
Iron Approved, Experimental Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7439-89-6, 15438-31-0 23925 27284
3
Hydroxyurea Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 127-07-1 3657
4
Deferoxamine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 70-51-9 2973
5
Deferiprone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 30652-11-0 2972
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
7
Mycophenolic acid Approved Phase 4,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
8
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-05-9 6006 143
9
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
10
Basiliximab Approved, Investigational Phase 4,Phase 2 152923-56-3, 179045-86-4
11
Nitric Oxide Approved Phase 4,Phase 2,Phase 3,Phase 1 10102-43-9 145068
12
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 57-27-2 5288826
13
Deferasirox Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 201530-41-8 5493381
14
Zoledronic Acid Approved Phase 4,Phase 2,Phase 3,Phase 1 118072-93-8 68740
15
Acetaminophen Approved Phase 4,Phase 2,Phase 1,Not Applicable 103-90-2 1983
16
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
17
Proguanil Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 500-92-5 4923
18
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 53123-88-9 46835353 6436030 5284616
19
Everolimus Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 159351-69-6 6442177 70789204
20
chloroquine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 54-05-7 2719
21
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 6740-88-1 3821
22
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 93-14-1 3516
23
Ribavirin Approved Phase 4,Phase 3,Phase 2,Not Applicable 36791-04-5 37542
24
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 2 198153-51-4 5360545
25
Prilocaine Approved Phase 4 721-50-6 4906
26
Mannitol Approved, Investigational Phase 4,Phase 3 69-65-8 453 6251
27
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
28
Racepinephrine Approved Phase 4 329-65-7 838
29
Sodium Citrate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 68-04-2
30
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2 437-38-7 3345
31
Zinc sulfate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7733-02-0
32
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6 32051
33
Hydromorphone Approved, Illicit Phase 4,Phase 3,Phase 2 466-99-9 5284570
34
Primaquine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90-34-6 4908
35
Ledipasvir Approved Phase 4,Phase 2 1256388-51-8 67505836
36
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
37
Sofosbuvir Approved Phase 4,Phase 2 1190307-88-0 45375808
38
Dapsone Approved, Investigational Phase 4,Phase 3 80-08-0 2955
39
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
40
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
41
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 1 104987-11-3 445643 439492 6473866
42
Amodiaquine Approved, Investigational Phase 4,Phase 1,Phase 2 86-42-0 2165
43
Sulfadoxine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 2447-57-6 17134
44
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 58-14-0 4993
45
tannic acid Approved Phase 4,Phase 2,Phase 1,Not Applicable 1401-55-4
46
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
47
Warfarin Approved Phase 4,Phase 2,Phase 1,Not Applicable 81-81-2 6691 54678486
48
Codeine Approved, Illicit Phase 4,Phase 1,Phase 2 76-57-3 5284371
49
Metformin Approved Phase 4,Early Phase 1 657-24-9 14219 4091
50
Ibuprofen Approved Phase 4,Phase 2,Not Applicable 15687-27-1 3672

Interventional clinical trials:

(show top 50) (show all 1076)
# Name Status NCT ID Phase Drugs
1 Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency Unknown status NCT02594904 Phase 4 Yinzhihuang Oral Liquid
2 Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC Unknown status NCT01795794 Phase 4 omeprazole
3 Mobile-Directly Observed Therapy on Adherence to Hydroxyurea Unknown status NCT02844673 Phase 4 Hydroxyurea
4 B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals Unknown status NCT01846923 Phase 4
5 The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study Unknown status NCT01323608 Phase 4 Vitamin D3;Placebo
6 Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major Unknown status NCT00103753 Phase 4 deferiprone
7 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Unknown status NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
8 Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin Completed NCT00491179 Phase 4 Pegylated interferon alfa-2a and ribavirin;Pegylated interferon alfa-2a and ribavirin
9 Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C Completed NCT00491244 Phase 4 Peginterferon alfa-2a and ribavirin;Peginterferon alfa-2a
10 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection Completed NCT00353418 Phase 4 Peginterferon alfa-2a;Ribavirin;Ribavirin
11 Evaluation of Ureteral Patency in the Post-indigo Carmine Era Completed NCT02677623 Phase 4 Pyridium;Sodium Fluorescein;Mannitol
12 Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3 Completed NCT00056862 Phase 4 Peginterferon alfa-2a;Peginterferon alfa-2a;Ribavirin
13 Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease Completed NCT00028093 Phase 4 Peginterferon alfa-2a with Ribavirin;Peginterferon alfa-2a
14 Long-Term Therapy With Ribavirin for Chronic Hepatitis C Completed NCT00001854 Phase 4 Ribavirin
15 Intranasal Fentanyl Versus Intravenous Morphine in the Treatment of Severe Painful Sickle Cell Crises in Children Completed NCT03682211 Phase 4 Fentanyl Citrate;Morphine sulphate
16 Zinc Supplementation on Cellular Immunity in Thalassemia Major Completed NCT03117192 Phase 4 Zinc Sulfate;Sucrose Syrup
17 Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions Completed NCT02731157 Phase 4 Rejuvesol
18 Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia Completed NCT01709838 Phase 4 ICL670 deferasirox
19 Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated Completed NCT01609192 Phase 4 Hydrea® (hydroxyurea )
20 Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis Completed NCT01482091 Phase 4 Fentanyl Citrate;Normal Saline
21 Efficacy Study of the Use of Sequential DFP-DFO Versus DFP Completed NCT00733811 Phase 4 Deferiprone (DFP) and Deferoxamine (DFO);Deferiprone (DFP)
22 Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events Completed NCT00346242 Phase 4 Zoledronic Acid
23 Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia Completed NCT03095326 Phase 4 Sucrose
24 Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH) Completed NCT02522104 Phase 4 Siklos
25 Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease Completed NCT02222246 Phase 4 Hydromorphone (Standardized, weight-based dosing);Morphine Sulfate (Standardized, weight-based dosing);Hydromorphone (Patient Specific dosing);Morphine Sulfate (Patient Specific dosing)
26 An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study) Completed NCT01736540 Phase 4
27 Post Hematopoietic Stem Cell Transplantation Completed NCT01610297 Phase 4 ICL670
28 Combo Chelation Trial Completed NCT00901199 Phase 4 Combo Chelation with Deferasirox (Exjade) and Desferal (DFO)
29 Pilot Study for Patients With Poor Response to Deferasirox Completed NCT00749515 Phase 4 Deferoxamine;Deferasirox
30 Safety and Tolerability of Low Dose Primaquine Completed NCT02434952 Phase 4 Dihydroartemisinin piperaquine (DHA PP);Primaquine
31 Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) Completed NCT00171301 Phase 4 Deferasirox
32 Efficacy Study in Removing Excess Iron From the Heart Completed NCT00105495 Phase 4 Ferriprox (deferiprone);Desferal (deferoxamine)
33 Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major Completed NCT00800761 Phase 4 Deferoxamine and Deferiprone;Deferoxamine
34 Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial Completed NCT03032666 Phase 4 sofosbuvir/velpatasvir
35 This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload. Completed NCT01250951 Phase 4 Deferasirox
36 Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency Completed NCT00243542 Phase 4 ACZONE Gel, 5%;Vehicle
37 Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection Completed NCT00707850 Phase 4 PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
38 Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload Completed NCT00564941 Phase 4 deferasirox
39 Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed NCT00867932 Phase 4 Eculizumab
40 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major Recruiting NCT02984475 Phase 4 Metformin
41 Colla Corii Asini Treating Anemia in Pregnant Women With Thalassemia(Presenting the Syndrome of Blood Deficiency) Recruiting NCT03374111 Phase 4 Colla corii asini;a Simulate Agent of Colla corii asini granule
42 Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Patients With Acute Sickle Cell Crises? Recruiting NCT03541980 Phase 4 Acetaminophen;Normal saline
43 Study on the Mechanism of Colla Corri Asini in the Treatment of Thalassemia Patients With Pregnancy Anemia Recruiting NCT03392298 Phase 4 Colla corii asini
44 Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major Recruiting NCT03171831 Phase 4 Busulfan;Cyclophosphamide;Fludarabine;Mycophenolate mofetil;Tacrolimus;Methotrexate;Thymoglobulin;Basiliximab
45 Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children Recruiting NCT03591575 Phase 4 Deferiprone oral solution;Placebo
46 Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias Recruiting NCT02041299 Phase 4 Deferiprone;Deferoxamine
47 Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE) Recruiting NCT03178643 Phase 4 Proguanil Oral Tablet;Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ);Dihydroartemisinin-Piperaquine (DP)
48 L-arginine Versus Sildenafil in Children With Beta Thalassemia Associated With Pulmonary Hypertension Recruiting NCT03402191 Phase 4 L-arginine;Sildenafil
49 Contraception in Women With Sickle Cell Disease Active, not recruiting NCT02594462 Phase 4 etonogestrel-releasing implant contraceptive
50 Endothelial Monocyte-activating Polypeptide-II in Egyptian Sickle Patients Active, not recruiting NCT03903133 Phase 4 Vitamin E

Search NIH Clinical Center for Hemolytic Anemia

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hemolytic Anemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hemolytic Anemia:
Hematopoietic stem cell transplantation for the treatment of genetic blood cell-related diseases
Embryonic/Adult Cultured Cells Related to Hemolytic Anemia:
Umbilical cord blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells (family)

Cochrane evidence based reviews: anemia, hemolytic

Sources

Genetic Tests for Hemolytic Anemia

About this section

Genetic tests related to Hemolytic Anemia:

# Genetic test Affiliating Genes
1 Hemolytic Anemia 30
Sources

Anatomical Context for Hemolytic Anemia

About this section

MalaCards organs/tissues related to Hemolytic Anemia:

42
Bone, Bone Marrow, Testes, Kidney, Liver, Heart, T Cells
Sources

Publications for Hemolytic Anemia

About this section

Articles related to Hemolytic Anemia:

(show top 50) (show all 3318)
# Title Authors Year
1
Etoricoxib-induced immune hemolytic anemia: first case presenting acute kidney failure. ( 30865300 )
2019
2
Severe hemolytic anemia due to combined α thalassemia and de novo Hemoglobin Sabine. ( 30673812 )
2019
3
Severe congenital hemolytic anemia caused by a novel compound heterozygous PKLR gene mutation in a Chinese boy. ( 30628965 )
2019
4
Abdominal pain in combination with an unexplained hemolytic anemia are crucial signs to test for paroxysmal nocturnal hemoglobinuria: A case report. ( 30656036 )
2019
5
Delayed Hemolytic Anemia after Treatment with Artesunate: Case Report and Literature Review. ( 30411691 )
2019
6
Prognosis of autoimmune hemolytic anemia in critically ill patients. ( 30536106 )
2019
7
Ceftriaxone-induced immune hemolytic anemia in a case with large vestibular aqueduct syndrome after cochlear implant. ( 30628967 )
2019
8
Cold type autoimmune hemolytic anemia- a rare manifestation of infectious mononucleosis; serum ferritin as an important biomarker. ( 30658594 )
2019
9
The Case | A 78-year-old woman with acute kidney injury and hemolytic anemia. ( 30665579 )
2019
10
Low dose rituximab in autoimmune hemolytic anemia: ten years after. ( 30670440 )
2019
11
The first reported case of drug-induced hemolytic anemia caused by dimethyl fumarate in a patient with multiple sclerosis. ( 30702749 )
2019
12
A Case of Pregnancy Complicated with Evans Syndrome with Sequential Development of Autoimmune Warm Antibody Hemolytic Anemia and Idiopathic Thrombocytopenic Purpura. ( 30733882 )
2019
13
Immunosensor for the Diagnostics of Autoimmune Hemolytic Anemia (AIHA) Based on Immobilization of a Monoclonal Antibody on a Layer of Silk Fibroin. ( 30764933 )
2019
14
Clinical and Laboratory Features of Autoimmune Hemolytic Anemia Associated with Immune Checkpoint Inhibitors. ( 30790338 )
2019
15
Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection. ( 30798587 )
2019
16
ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats. ( 30806491 )
2019
17
Transient appearance of ring sideroblasts in peripheral blood in the acute phase of secondary hemolytic anemia. ( 30819781 )
2019
18
Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer. ( 30828042 )
2019
19
Autoimmune Hemolytic Anemia, Erythrophagocytosis and Liver Dysfunction After Cefixime Use for Urinary Tract Infection in a Child. ( 30828180 )
2019
20
Ceftriaxone-Induced Immune Hemolytic Anemia: In Vitro Reversal with Peptide Inhibitor of Complement C1 (PIC1). ( 30838143 )
2019
21
ACVIM consensus statement on the treatment of immune-mediated hemolytic anemia in dogs. ( 30847984 )
2019
22
Hepatosplenic T cell lymphoma: a unifying entity in a patient with hemolytic anemia, massive splenomegaly, and liver dysfunction. ( 29766398 )
2018
23
Increased number of tissue factor protein expressing thrombocytes in canine idiopathic immune mediated hemolytic anemia. ( 29695321 )
2018
24
Importance of the Average Glucose Level and Estimated Glycated Hemoglobin in a Diabetic Patient with Hereditary Hemolytic Anemia and Liver Cirrhosis. ( 29225250 )
2018
25
Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia. ( 29911929 )
2018
26
Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report. ( 29340837 )
2018
27
Paraneoplastic Auto-immune Hemolytic Anemia: An Unusual Sequela of Enteric Duplication Cyst. ( 29277816 )
2018
28
Methylene blue-induced Heinz body hemolytic anemia in a premature neonate. ( 29314195 )
2018
29
Successful treatment of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation with bortezomib. ( 29345206 )
2018
30
Microangiopathic Hemolytic Anemia Following Three Different Species of Hump-Nosed Pit Viper (Genus: Hypnale) Envenoming in Sri Lanka. ( 29361387 )
2018
31
Hemolytic anemia due to native valve subacute endocarditis with<i>Actinomyces israelii</i>infection. ( 29445480 )
2018
32
A Case Report of Congenital Non-spherocytic Hemolytic Anemia in a Patient from India. ( 29904619 )
2018
33
Effects of therapeutic plasma exchange on serum immunoglobulin concentrations in a dog with refractory immune-mediated hemolytic anemia. ( 29641335 )
2018
34
Identification of a Novel Mutation in the SEC23B Gene Associated With Congenital Dyserythropoietic Anemia Type II Through the Use of Next-generation Sequencing Panel in an Undiagnosed Case of Nonimmune Hereditary Hemolytic Anemia. ( 29846281 )
2018
35
Mixed IgM cold and IgG warm autoimmune hemolytic anemia complicated by acral gangrene. ( 29683507 )
2018
36
Ominous comorbidities: Small ventricular septal defect and warm autoimmune hemolytic anemia. ( 29440848 )
2018
37
Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab. ( 29359614 )
2018
38
Factors associated with immune hemolytic anemia after pediatric liver transplantation. ( 29885007 )
2018
39
Splenic myeloid metaplasia in warm autoimmune hemolytic anemia (wAIHA): a retrospective study. ( 29662860 )
2018
40
Molecular detection of Mycoplasma ovis in an outbreak of hemolytic anemia in sheep from Veracruz, Mexico. ( 29934796 )
2018
41
R Inguinal/R Scrotum Extramammary Paget's Disease with Diffuse Spine Metastasis Complicated by Microangiopathic Hemolytic Anemia. ( 29805822 )
2018
42
Spurious thrombocytosis in the setting of hemolytic anemia and microcytosis secondary to extensive burn injury. ( 29391327 )
2018
43
Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis. ( 29359617 )
2018
44
Eluate testing with monospecific antisera unmasks multiple immunoglobulin classes and identifies frequent IgA involvement in severe autoimmune hemolytic anemia. ( 29716828 )
2018
45
Whole-exome analysis to detect congenital hemolytic anemia mimicking congenital dyserythropoietic anemia. ( 29936674 )
2018
46
Features of peripheral CD8<sup>+</sup>CD57<sup>+</sup> lymphocytes in patients with autoimmune hemolytic anemia. ( 29845877 )
2018
47
Efficacy of D- red blood cell transfusion and rituximab therapy in autoimmune hemolytic anemia with anti-D and panreactive autoantibodies arising after hematopoietic stem cell transplant. ( 29664112 )
2018
48
Microangiopathic hemolytic anemia as initial presentation of recurrent colon cancer. ( 29963526 )
2018
49
Influence of immune-mediated hemolytic anemia on flow velocities in the portal vein and caudal vena cava measured by use of pulsed-wave Doppler ultrasonography in dogs. ( 29688778 )
2018
50
Durable responses in refractory autoimmune hemolytic anemia with alemtuzumab. ( 29334337 )
2018
Sources

Variations for Hemolytic Anemia

About this section

ClinVar genetic disease variations for Hemolytic Anemia:

6 (show top 50) (show all 140)
# Gene Variation Type Significance SNP ID Assembly Location
1 HBB NM_000518.5(HBB): c.127T> C (p.Phe43Leu) single nucleotide variant Pathogenic rs33924146 GRCh38 Chromosome 11, 5226765: 5226765
2 HBB NM_000518.5(HBB): c.127T> C (p.Phe43Leu) single nucleotide variant Pathogenic rs33924146 GRCh37 Chromosome 11, 5247995: 5247995
3 HBB NM_000518.4(HBB): c.127T> G (p.Phe43Val) single nucleotide variant Pathogenic rs33924146 GRCh37 Chromosome 11, 5247995: 5247995
4 HBB NM_000518.4(HBB): c.127T> G (p.Phe43Val) single nucleotide variant Pathogenic rs33924146 GRCh38 Chromosome 11, 5226765: 5226765
5 SLC4A1 NM_000342.3(SLC4A1): c.166A> G (p.Lys56Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs5036 GRCh37 Chromosome 17, 42338945: 42338945
6 SLC4A1 NM_000342.3(SLC4A1): c.166A> G (p.Lys56Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs5036 GRCh38 Chromosome 17, 44261577: 44261577
7 SLC4A1 NM_000342.3(SLC4A1): c.118G> A (p.Glu40Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs45562031 GRCh37 Chromosome 17, 42338993: 42338993
8 SLC4A1 NM_000342.3(SLC4A1): c.118G> A (p.Glu40Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs45562031 GRCh38 Chromosome 17, 44261625: 44261625
9 SLC4A1 NM_000342.3(SLC4A1): c.2561C> T (p.Pro854Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs2285644 GRCh37 Chromosome 17, 42328621: 42328621
10 SLC4A1 NM_000342.3(SLC4A1): c.2561C> T (p.Pro854Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs2285644 GRCh38 Chromosome 17, 44251253: 44251253
11 SLC4A1 NM_000342.3(SLC4A1): c.2701C> T (p.Arg901Trp) single nucleotide variant Uncertain significance rs201265160 GRCh37 Chromosome 17, 42327861: 42327861
12 SLC4A1 NM_000342.3(SLC4A1): c.2701C> T (p.Arg901Trp) single nucleotide variant Uncertain significance rs201265160 GRCh38 Chromosome 17, 44250493: 44250493
13 SLC4A1 NM_000342.3(SLC4A1): c.2712C> T (p.Tyr904=) single nucleotide variant Benign/Likely benign rs45519733 GRCh37 Chromosome 17, 42327850: 42327850
14 SLC4A1 NM_000342.3(SLC4A1): c.2712C> T (p.Tyr904=) single nucleotide variant Benign/Likely benign rs45519733 GRCh38 Chromosome 17, 44250482: 44250482
15 SLC4A1 NM_000342.3(SLC4A1): c.2688T> C (p.Asp896=) single nucleotide variant Benign/Likely benign rs45497993 GRCh37 Chromosome 17, 42327874: 42327874
16 SLC4A1 NM_000342.3(SLC4A1): c.2688T> C (p.Asp896=) single nucleotide variant Benign/Likely benign rs45497993 GRCh38 Chromosome 17, 44250506: 44250506
17 SLC4A1 NM_000342.3(SLC4A1): c.2584G> A (p.Val862Ile) single nucleotide variant Benign/Likely benign rs5026 GRCh37 Chromosome 17, 42328598: 42328598
18 SLC4A1 NM_000342.3(SLC4A1): c.2584G> A (p.Val862Ile) single nucleotide variant Benign/Likely benign rs5026 GRCh38 Chromosome 17, 44251230: 44251230
19 SLC4A1 NM_000342.3(SLC4A1): c.1953C> T (p.His651=) single nucleotide variant Benign/Likely benign rs5021 GRCh37 Chromosome 17, 42331968: 42331968
20 SLC4A1 NM_000342.3(SLC4A1): c.1953C> T (p.His651=) single nucleotide variant Benign/Likely benign rs5021 GRCh38 Chromosome 17, 44254600: 44254600
21 SLC4A1 NM_000342.3(SLC4A1): c.1770G> A (p.Lys590=) single nucleotide variant Benign/Likely benign rs35807245 GRCh38 Chromosome 17, 44255703: 44255703
22 SLC4A1 NM_000342.3(SLC4A1): c.1770G> A (p.Lys590=) single nucleotide variant Benign/Likely benign rs35807245 GRCh37 Chromosome 17, 42333071: 42333071
23 SLC4A1 NM_000342.3(SLC4A1): c.1323G> A (p.Leu441=) single nucleotide variant Benign/Likely benign rs5017 GRCh37 Chromosome 17, 42335135: 42335135
24 SLC4A1 NM_000342.3(SLC4A1): c.1323G> A (p.Leu441=) single nucleotide variant Benign/Likely benign rs5017 GRCh38 Chromosome 17, 44257767: 44257767
25 SLC4A1 NM_000342.3(SLC4A1): c.1249C> T (p.Leu417=) single nucleotide variant Benign/Likely benign rs5015 GRCh37 Chromosome 17, 42335387: 42335387
26 SLC4A1 NM_000342.3(SLC4A1): c.1249C> T (p.Leu417=) single nucleotide variant Benign/Likely benign rs5015 GRCh38 Chromosome 17, 44258019: 44258019
27 SLC4A1 NM_000342.3(SLC4A1): c.924G> A (p.Leu308=) single nucleotide variant Benign/Likely benign rs5013 GRCh37 Chromosome 17, 42335944: 42335944
28 SLC4A1 NM_000342.3(SLC4A1): c.924G> A (p.Leu308=) single nucleotide variant Benign/Likely benign rs5013 GRCh38 Chromosome 17, 44258576: 44258576
29 SLC4A1 NM_000342.3(SLC4A1): c.113A> C (p.Asp38Ala) single nucleotide variant Benign/Likely benign rs5035 GRCh37 Chromosome 17, 42338998: 42338998
30 SLC4A1 NM_000342.3(SLC4A1): c.113A> C (p.Asp38Ala) single nucleotide variant Benign/Likely benign rs5035 GRCh38 Chromosome 17, 44261630: 44261630
31 SLC4A1 NM_000342.3(SLC4A1): c.16-14G> A single nucleotide variant Benign/Likely benign rs145502796 GRCh38 Chromosome 17, 44262740: 44262740
32 SLC4A1 NM_000342.3(SLC4A1): c.16-14G> A single nucleotide variant Benign/Likely benign rs145502796 GRCh37 Chromosome 17, 42340108: 42340108
33 SLC4A1 NM_000342.3(SLC4A1): c.*1832G> A single nucleotide variant Uncertain significance rs886052988 GRCh37 Chromosome 17, 42325994: 42325994
34 SLC4A1 NM_000342.3(SLC4A1): c.*1832G> A single nucleotide variant Uncertain significance rs886052988 GRCh38 Chromosome 17, 44248626: 44248626
35 SLC4A1 NM_000342.3(SLC4A1): c.*1721G> A single nucleotide variant Likely benign rs62078947 GRCh37 Chromosome 17, 42326105: 42326105
36 SLC4A1 NM_000342.3(SLC4A1): c.*1721G> A single nucleotide variant Likely benign rs62078947 GRCh38 Chromosome 17, 44248737: 44248737
37 SLC4A1 NM_000342.3(SLC4A1): c.*1676A> G single nucleotide variant Uncertain significance rs745898810 GRCh37 Chromosome 17, 42326150: 42326150
38 SLC4A1 NM_000342.3(SLC4A1): c.*1676A> G single nucleotide variant Uncertain significance rs745898810 GRCh38 Chromosome 17, 44248782: 44248782
39 SLC4A1 NM_000342.3(SLC4A1): c.*1606_*1608dupAAA duplication Uncertain significance rs57466226 GRCh37 Chromosome 17, 42326218: 42326220
40 SLC4A1 NM_000342.3(SLC4A1): c.*1606_*1608dupAAA duplication Uncertain significance rs57466226 GRCh38 Chromosome 17, 44248850: 44248852
41 SLC4A1 NM_000342.3(SLC4A1): c.*1608delA deletion Uncertain significance rs57466226 GRCh37 Chromosome 17, 42326218: 42326218
42 SLC4A1 NM_000342.3(SLC4A1): c.*1608delA deletion Uncertain significance rs57466226 GRCh38 Chromosome 17, 44248850: 44248850
43 SLC4A1 NM_000342.3(SLC4A1): c.*1198A> T single nucleotide variant Uncertain significance rs886052992 GRCh38 Chromosome 17, 44249260: 44249260
44 SLC4A1 NM_000342.3(SLC4A1): c.*1198A> T single nucleotide variant Uncertain significance rs886052992 GRCh37 Chromosome 17, 42326628: 42326628
45 SLC4A1 NM_000342.3(SLC4A1): c.*897G> A single nucleotide variant Likely benign rs5030 GRCh38 Chromosome 17, 44249561: 44249561
46 SLC4A1 NM_000342.3(SLC4A1): c.*897G> A single nucleotide variant Likely benign rs5030 GRCh37 Chromosome 17, 42326929: 42326929
47 SLC4A1 NM_000342.3(SLC4A1): c.2210C> T (p.Ala737Val) single nucleotide variant Uncertain significance rs886052997 GRCh38 Chromosome 17, 44253219: 44253219
48 SLC4A1 NM_000342.3(SLC4A1): c.2210C> T (p.Ala737Val) single nucleotide variant Uncertain significance rs886052997 GRCh37 Chromosome 17, 42330587: 42330587
49 SLC4A1 NM_000342.3(SLC4A1): c.1637A> G (p.Asp546Gly) single nucleotide variant Uncertain significance rs886052998 GRCh38 Chromosome 17, 44255836: 44255836
50 SLC4A1 NM_000342.3(SLC4A1): c.1637A> G (p.Asp546Gly) single nucleotide variant Uncertain significance rs886052998 GRCh37 Chromosome 17, 42333204: 42333204
Sources

Expression for Hemolytic Anemia

About this section
Search GEO for disease gene expression data for Hemolytic Anemia.
Sources

Pathways for Hemolytic Anemia

About this section

Pathways related to Hemolytic Anemia according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Metabolism 67
Show member pathways
 13.73 AK1 ALDOA G6PD GCLC GPI GSS
2
Glycosaminoglycan metabolism 67
Show member pathways
 12.63 ALDOA G6PD GPI HK1 PGK1 PKLR
3
Glucose metabolism 67
Show member pathways
 12.41 ALDOA GPI HK1 PGK1 PKLR
4
Glucose / Energy Metabolism 4
12.31 ALDOA G6PD HBB HK1
5
L1CAM interactions 67
Show member pathways
 11.81 ANK1 SPTA1 SPTB
6
Carbon metabolism 38
Show member pathways
 11.76 ALDOA G6PD GPI HK1 PGK1 PKLR
7
HIF-1 signaling pathway 38
11.69 ALDOA HK1 PGK1
8
Citrate cycle (TCA cycle) 38
Show member pathways
 11.64 ALDOA HK1 PGK1 PKLR
9
HIF-1-alpha transcription factor network 1
11.47 ALDOA HK1 PGK1
10
Pentose phosphate pathway 38 1 1
Show member pathways
 11.45 ALDOA G6PD GPI
11
Interaction between L1 and Ankyrins 67
11.02 ANK1 SPTA1 SPTB
12
Abacavir Pathway, Pharmacokinetics/Pharmacodynamics 62
10.61 PGK1 PKLR
13
Cori Cycle 1
10.13 G6PD GPI HK1 PGK1
14
Pentose Phosphate Pathway (Erythrocyte), Pharmacodynamics 62
10.11 G6PD GPI HK1
Sources

GO Terms for Hemolytic Anemia

About this section

Cellular components related to Hemolytic Anemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.96 AK1 ALDOA CD59 G6PD GPI GSS
2 ficolin-1-rich granule lumen GO:1904813 9.61 ALDOA GPI HBB
3 cytoplasmic side of plasma membrane GO:0009898 9.5 ANK1 G6PD SPTA1
4 spectrin GO:0008091 9.4 SPTA1 SPTB
5 intrinsic component of the cytoplasmic side of the plasma membrane GO:0031235 9.37 SPTA1 SPTB
6 cortical cytoskeleton GO:0030863 9.13 EPB42 SLC4A1 SPTA1
7 spectrin-associated cytoskeleton GO:0014731 8.8 ANK1 SPTA1 SPTB
8 cytosol GO:0005829 10 AK1 ALDOA ANK1 G6PD GCLC GPI

Biological processes related to Hemolytic Anemia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 carbohydrate metabolic process GO:0005975 9.76 G6PD GPI HK1 PKLR
2 regulation of cell shape GO:0008360 9.73 ALDOA EPB42 SPTA1
3 ER to Golgi vesicle-mediated transport GO:0006888 9.73 ANK1 CD59 SPTA1 SPTB
4 muscle cell cellular homeostasis GO:0046716 9.55 ALDOA PGK1
5 actin filament capping GO:0051693 9.54 SPTA1 SPTB
6 gluconeogenesis GO:0006094 9.54 ALDOA GPI PGK1
7 regulation of blood vessel size GO:0050880 9.52 GCLC HBB
8 glutathione biosynthetic process GO:0006750 9.51 GCLC GSS
9 bicarbonate transport GO:0015701 9.5 HBB RHAG SLC4A1
10 erythrocyte maturation GO:0043249 9.49 EPB42 G6PD
11 response to xenobiotic stimulus GO:0009410 9.48 GCLC GSS
12 response to cadmium ion GO:0046686 9.43 GCLC GPI GSS
13 cellular ion homeostasis GO:0006873 9.4 RHAG SLC4A1
14 glycolytic process GO:0006096 9.35 ALDOA GPI HK1 PGK1 PKLR
15 glucose 6-phosphate metabolic process GO:0051156 9.33 G6PD GPI HK1
16 canonical glycolysis GO:0061621 9.02 ALDOA GPI HK1 PGK1 PKLR

Molecular functions related to Hemolytic Anemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.87 AK1 EPB42 GCLC GSS HK1 PGK1
2 catalytic activity GO:0003824 9.67 ALDOA GCLC HK1 PKLR
3 magnesium ion binding GO:0000287 9.46 GCLC GSS NT5C3A PKLR
4 glucose binding GO:0005536 9.26 G6PD HK1
5 structural constituent of cytoskeleton GO:0005200 9.26 ANK1 EPB42 SPTA1 SPTB
6 ankyrin binding GO:0030506 8.8 RHAG SLC4A1 SPTB
Sources

Sources for Hemolytic Anemia

About this section
3 CDC
7 CNVD
9 Cosmic